Lilly in dock over improper marketing
Eli Lilly is the new drug giant to be raked over hot coals for improper marketing of its drugs.
Read MoreAuthor: Katrina Megget
Amgen gets mixed news over denosumab
Amgen has received both good and bad news regarding the recommended approval of its eagerly anticipated osteoporosis drug Prolia (denosumab) in the USA.
Read MoreSupport for British NHS on Twitter
Opposition to President Barack Obama’s healthcare reform plans has caused an uproar in the UK with even the British Prime Minister supporting the NHS on Twitter.
Read MoreWoodcock investigated for conflict of interest
The US Food and Drug Administration’s Janet Woodcock is under investigation for an alleged conflict of interest involving two generic drugmakers and approval of their drugs.
Read MoreNovo diabetes drug launched in UK
The potential “holy grail” to treat diabetes has been launched in the UK.
Read More- Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC
- Cenrifki approved in EU for secondary progressive multiple sclerosis
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
